Drugs Made In America Acquisition Corp. financial data

Symbol
DMAA, DMAAR, DMAAU on Nasdaq
Location
Fort Lauderdale, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 18 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 8.1% %
Debt-to-equity -103% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33,517,143 shares
Common Stock, Shares, Outstanding 10,517,143 shares
Common Stock, Value, Issued $1,052 USD

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $263,703 USD 82%
Operating Income (Loss) $263,703 USD -82%
Nonoperating Income (Expense) $2,448,266 USD
Net Income (Loss) Attributable to Parent $2,184,563 USD

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $28,196 USD
Assets $237,632,428 USD
Accrued Liabilities, Current $302,623 USD
Liabilities, Current $456,611 USD
Liabilities $7,356,611 USD
Retained Earnings (Accumulated Deficit) $6,720,645 USD
Stockholders' Equity Attributable to Parent $7,328,415 USD -4345%
Liabilities and Equity $237,632,428 USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 220,000,000 shares
Common Stock, Shares, Issued 10,517,143 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $717 USD -66%
Preferred Stock, Shares Authorized 1,000,000 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares